May 9, 2016
The Pharmaceuticals and Medical Devices Agency (PMDA) said on May 6 that it is reviewing the risk of osteonecrosis of the external auditory canal for seven bisphosphonate preparations, a move that is likely to result in label changes. The seven...read more